A new automated drug safety surveillance tool may help identify adverse drug reactions not detected in pre-market clinical trials using multiple data sources.
Therapeutic drugs often have side effects that are not picked up during pre-market clinical trials. For this reason, even after their market release, they need to be continuously monitored for new or incompletely documented adverse drug reactions (ADRs), known as “signals”
Further information: Leveraging and enriching drug safety monitoring